Ongoing Clinical Trials
Clinical TrialsAs part of its mission to make a clinically meaningful difference for patients with cancers of the liver, Delcath Systems is deeply committed to the clinical development of Percutaneous Hepatic Perfusion (PHP®)*. To date, PHP has been the subject of peer-reviewed papers, as well as multiple oral and poster presentations. Additional trials are underway to examine the use of PHP in metastatic ocular melanoma, as well as primary liver cancer (HCC/ICC).
* For Investigational Use Only in the U.S.
Delcath does not make any claim whatsoever, real or implied, about the efficacy or safety of any therapy, drug, system, or technique under active research.